← All candidates
Two insider buys in the last year — $62.1K in all.
22 filings on record.
HROWHARROW, INC.
NasdaqGM · Healthcare · $1.27B
$33.84
-0.68% · Sep 15
Two insider buys in the last year — $62.1K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 2 buys● 3 sells◆ 13 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 2×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what HROW ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$1.27B
Float
28.9M
77% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
11.9
Price / sales
4.6
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Graves Adrienne L
Bought $31.1K on May 18 — 1,000 sh @ $31.07, held direct, 100% of their stake.
No completed positions to measure
Director
Silvernail Lauren P
Bought $31.0K on May 18 — 1,000 sh @ $31.00, held direct, 100% of their stake.
No completed positions to measure
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
11 more transactions on Pro →Context
Wall St
$67.75 avg target
+100.2% vs today · 8 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 3 quarters beat
Q1 '26−$0.74 act−$0.41
Q3 '25$0.33 act+$0.04
Q2 '25$0.24 act+$0.20
Coverage
GROW Small Cap Equity Fund Covered Its Position in Harrow (HROW) in Q1Insider Monkey · 06-23Is Harrow, Inc. (HROW) A Good Stock To Buy Now?Insider Monkey · 06-13Can Harrow’s (HROW) VERKAZIA Relaunch Redefine Its Niche Ophthalmic Strategy?Simply Wall St. · 06-12What Does Cantor Fitzgerald Think About Harrow (HROW) After Cutting Its Price Target?Insider Monkey · 06-04
The file stays open
22 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice